For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is ...
Long-term inhaled corticosteroid (ICS) use for chronic obstructive pulmonary disease/ COPD (lung disease) may increase the ...
News Medical on MSN4d
Long-term inhaled corticosteroid use for COPD linked to serious long-term health risksInhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma/COPD overlap or frequent ...
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Background and goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma ...
1d
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...
Pharmaceutical Technology on MSN4d
EMA to review GSK’s Nucala for COPD treatment expansionThe EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.
Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback